Qube Research & Technologies LTD Esperion Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 228,730 shares of ESPR stock, worth $416,288. This represents 0.0% of its overall portfolio holdings.
Number of Shares
228,730
Previous 750,784
69.53%
Holding current value
$416,288
Previous $1.24 Million
59.37%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ESPR
# of Institutions
215Shares Held
129MCall Options Held
1.78MPut Options Held
1.27M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$44.6 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$25.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$18.1 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$11.5 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $121M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...